IBDEI0PU ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11616,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,11616,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,11617,0)
 ;;=I13.2^^46^563^7
 ;;^UTILITY(U,$J,358.3,11617,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11617,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,11617,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,11617,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,11618,0)
 ;;=I70.1^^46^563^3
 ;;^UTILITY(U,$J,358.3,11618,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11618,1,3,0)
 ;;=3^Atherosclerosis of Renal Artery
 ;;^UTILITY(U,$J,358.3,11618,1,4,0)
 ;;=4^I70.1
 ;;^UTILITY(U,$J,358.3,11618,2)
 ;;=^269760
 ;;^UTILITY(U,$J,358.3,11619,0)
 ;;=I77.3^^46^563^2
 ;;^UTILITY(U,$J,358.3,11619,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11619,1,3,0)
 ;;=3^Arterial Fibromuscular Dysplasia
 ;;^UTILITY(U,$J,358.3,11619,1,4,0)
 ;;=4^I77.3
 ;;^UTILITY(U,$J,358.3,11619,2)
 ;;=^5007812
 ;;^UTILITY(U,$J,358.3,11620,0)
 ;;=E26.02^^46^563^5
 ;;^UTILITY(U,$J,358.3,11620,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11620,1,3,0)
 ;;=3^Glucocorticoid-Remediable Aldosteronism
 ;;^UTILITY(U,$J,358.3,11620,1,4,0)
 ;;=4^E26.02
 ;;^UTILITY(U,$J,358.3,11620,2)
 ;;=^329904
 ;;^UTILITY(U,$J,358.3,11621,0)
 ;;=I12.9^^46^563^14
 ;;^UTILITY(U,$J,358.3,11621,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11621,1,3,0)
 ;;=3^Hypertensive CKD Stage 1-4
 ;;^UTILITY(U,$J,358.3,11621,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,11621,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,11622,0)
 ;;=I12.0^^46^563^15
 ;;^UTILITY(U,$J,358.3,11622,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11622,1,3,0)
 ;;=3^Hypertensive CKD Stage 5 or ESRD
 ;;^UTILITY(U,$J,358.3,11622,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,11622,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,11623,0)
 ;;=I13.0^^46^563^6
 ;;^UTILITY(U,$J,358.3,11623,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11623,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney
 ;;^UTILITY(U,$J,358.3,11623,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,11623,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,11624,0)
 ;;=I13.10^^46^563^9
 ;;^UTILITY(U,$J,358.3,11624,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11624,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney
 ;;^UTILITY(U,$J,358.3,11624,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,11624,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,11625,0)
 ;;=I15.1^^46^563^11
 ;;^UTILITY(U,$J,358.3,11625,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11625,1,3,0)
 ;;=3^Hypertension Secondary to Oth Renal Disorders
 ;;^UTILITY(U,$J,358.3,11625,1,4,0)
 ;;=4^I15.1
 ;;^UTILITY(U,$J,358.3,11625,2)
 ;;=^5007072
 ;;^UTILITY(U,$J,358.3,11626,0)
 ;;=I15.2^^46^563^10
 ;;^UTILITY(U,$J,358.3,11626,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11626,1,3,0)
 ;;=3^Hypertension Secondary to Endocrine Disorders
 ;;^UTILITY(U,$J,358.3,11626,1,4,0)
 ;;=4^I15.2
 ;;^UTILITY(U,$J,358.3,11626,2)
 ;;=^5007073
 ;;^UTILITY(U,$J,358.3,11627,0)
 ;;=I50.1^^46^563^16
 ;;^UTILITY(U,$J,358.3,11627,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11627,1,3,0)
 ;;=3^Left Ventricular Failure
 ;;^UTILITY(U,$J,358.3,11627,1,4,0)
 ;;=4^I50.1
 ;;^UTILITY(U,$J,358.3,11627,2)
 ;;=^5007238
 ;;^UTILITY(U,$J,358.3,11628,0)
 ;;=E26.09^^46^563^17
 ;;^UTILITY(U,$J,358.3,11628,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,11628,1,3,0)
 ;;=3^Primary Hyperaldosteronism,Other
 ;;^UTILITY(U,$J,358.3,11628,1,4,0)
 ;;=4^E26.09
